Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia
Metrics: PDF 282 views | Full Text 382 views | ?
Jan Philipp Bewersdorf1 and Amer M. Zeidan1,2
1 Department of Internal Medicine, Section of Hematology, Yale School of Medicine, New Haven, CT, USA
2 Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, CT, USA
|Amer M. Zeidan,||email:||firstname.lastname@example.org|
Keywords: acute myeloid leukemia; AML; PLK-1 inhibitor; onvansertib; volasertib
Received: February 24, 2021 Accepted: March 08, 2021 Published: June 22, 2021
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.